Randoimized controlled trial of recombinant human granulocyte-macrophage colony-stimulating factor for the treatment of chronic hepatitis C

Cytokine

Volumn 12, Issue 2, 2000, Pages 165-170

  Carreño, Vicente ^a,b   Martín, Julio ^a,b   Pardo, Margarita ^a,b   Brotons, Alvaro ^a   Anchía, Pedro ^c   Navas, Sonia ^a,b   Fernández, Mario ^a   Arocena, Carlos ^a   Quiroga, Juan Antonio ^a,b  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^b Fund El Estud Las Hepat Virales   (Spain)

^c Schering Plough   (Spain)

Author keywords

2',5' Oligoadenylate synthetase activity; Chronic hepatitis C virus (HCV) infection; Granulocyte macrophage colony stimulating factor (GM CSF); Interferon (IFN) therapeutic use; Therapeutic use

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; VIRUS RNA; ANTIVIRUS AGENT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT PROTEIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; ENZYME ACTIVITY; EOSINOPHIL; EOSINOPHILIA; FEMALE; FLU LIKE SYNDROME; HAIR LOSS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LEUKOCYTE COUNT; LEUKOCYTOSIS; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION; THROMBOCYTOPENIA; VIREMIA; WEIGHT REDUCTION; ADOLESCENT; DRUG COMBINATION; DRUG ERUPTION; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; DRUG ERUPTIONS; DRUG THERAPY, COMBINATION; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; VIREMIA;

EID: 0033621730     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1006/cyto.1999.0530     Document Type: Article

References (16)

1. Seeff LB. Natural history of hepatitis C. Hepatology. 26:1997;21S-28S.
2. Shakil AO, Conry-Cantilena C, Alter HJ, Hayashi P, Kleiner DE, Tedeschi V, Krawczynski K, Conjeevaram HS, Sallie R, Di Bisceglie AM. Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. Ann Intern Med. 123:1995;330-337.
3. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med. 336:1997;347-356.
4. Nemunaitis J. A comparative review of colony-stimulating factors. Drugs. 54:1997;709-729.
5. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. N Engl J Med. 327:1992;99-106.
6. Crowe SM, Lopez A. GM-CSF and its effects on replication of HIV-1 in cells of the macrophage lineage. J Leukocyte Biol. 62:1997;41-48.
7. Martín J, Bosch O, Moraleda G, Bartolomé J, Quiroga JA, Carreño V. Pilot study of recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of chronic hepatitis B. Hepatology. 18:1993;775-780.
8. Carreño V, Parra A, Navas S, Quiroga JA. Granulocyte-macrophage colony-stimulating factor as adjuvant therapy for interferon-α treatment of chronic hepatitis C. Cytokine. 8:1996;318-322.
9. Martín J, Quiroga JA, Navas S, Pardo M, Carreño V. Modulation by Biologic Response Modifiers of Hepatitis C Virus Antigen-Independent Cytokine Secretion in Blood Mononuclear Cells. Cytokine. 11:1999;267-273.
10. Geissler M, Gesien A, Tokushige K, Wands JR. Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids. J Immunol. 158:1997;1231-1123.
11. Van Thiel DH, Friedlander L, Kania RJ, Molloy PJ, Hassanein T, Faruki H. A preliminary experience with GM-CSF plus interferon in patients with HBV and HCV resistant to interferon therapy. J Viral Hepat. 4:1997;101-106.
12. Gutterman JU. Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci U S A. 91:1994;1198-1205.
13. Tilg H. New insights into the mechanism of interferon alfa: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology. 112:1997;1017-1021.
14. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1:1981;431-435.
15. Desmet VJ, Gerber MA, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 19:1994;1513-1520.
16. Navas S, Castillo I, Martín J, Quiroga JA, Bartolomé J, Carreño V. Concordance of hepatitis C virus typing methods based on RFLP analysis in 5′ non-coding region, and NS4 serotyping, but not in core-PCR or a line probe assay. J Clin Microbiol. 35:1997;317-321.